← 홈

Antibody · VEGF

234개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 234개
AntibodystaleRoswell Park Cancer InstitutePhase 2

Gemcitabine, Capecitabine and Bevacizumab (Gemcitabine, Capecitabine and Bevacizumab)

Cholangiocarcinoma · Cholangiocarcinoma

#Cholangiocarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodyBiologicstaleHenan Provincial People's Hospi…Preclinical

Gene evolution and molecular response under Bevacizumab treatment (Gene evolution and molecular response under Bevacizumab treatment)

Genetic Change · Genetic Change

#GeneticChange#Antibody#Preclinical#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleTianjin Medical University Canc…Phase 2

durvalumab (Imfinzi, HAIC+Durvalumab+Tremelimumab+Bevacizumab)

Unrescetable Hepatocellular Carcinoma · Unrescetable Hepatocellular Carcinoma

#UnrescetableHepatocellularCarcin#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 1

HAIC、Bevacizumab、Camrelizumab (HAIC、Bevacizumab、Camrelizumab)

Metastatic Liver Cancer · Metastatic Liver Cancer

#MetastaticLiverCancer#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab (HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab)

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 3

HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab (HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab)

Colorectal Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleShuhong YiPhase 2

atezolizumab (Tecentriq, Hepatic arterial infusion chemotherapy + Atezolizumab and bevacizumab)

Recurrent Liver Cancer After Liver Transplantation · Recurrent Liver Cancer After Liver Trans

#RecurrentLiverCancerAfterLiverTr#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleHunan Province Tumor HospitalPhase 2

IBI-323 combined with bevacizumab plus Platinum (IBI-323 combined with bevacizumab plus Platinum)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleKhon Kaen UniversityPhase 3

Intralesional injection of bevacizumab (Intralesional injection of bevacizumab)

Pterygium; Inflammation · Pterygium

#Pterygium#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleEastern Regional Medical CenterPhase 1

Intraperitoneal Bevacizumab (Intraperitoneal Bevacizumab)

Malignant Ascites · Malignant Ascites

#MalignantAscites#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleFudan UniversityPhase 2

Iparomlimab and Tuvoraleimab injection+Bevacizumab+Pemetrexed+Cisplatin (Iparomlimab and Tuvoraleimab injection+Bevacizumab+Pemetrexed+Cisplatin)

Mesothelioma · Mesothelioma

#Mesothelioma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleEli LillyPhase 2

Irinotecan Liposomes (II, Irinotecan Liposomes, Irinotecan Liposomes (II)+Cetuximab+Bevacizumabl)

Colorectal Cancer Metastatic · Colorectal Cancer Metastatic

#ColorectalCancerMetastatic#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleThe Fourth Affiliated Hospital …Phase 2

Irinotecan liposome combined with capecitabine, bevacizumab and camrelizumab (Irinotecan liposome combined with capecitabine, bevacizumab and camrelizumab)

Metastatic Colorectal Cancer (CRC) · Metastatic Colorectal Cancer (CRC)

#MetastaticColorectalCancerCRC#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 1

JS001+Bevacizumab (JS001+Bevacizumab)

Advanced Malignant Solid Tumors · Advanced Malignant Solid Tumors

#AdvancedMalignantSolidTumors#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleM.D. Anderson Cancer CenterPhase 1

LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide (LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide)

Metastatic Esophageal; Gastric Cancer · Metastatic Esophageal

#MetastaticEsophageal#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleM.D. Anderson Cancer CenterPhase 1

LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide (LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide)

Metastatic Esophageal; Gastric Cancer · Metastatic Esophageal

#MetastaticEsophageal#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleThe First Hospital of Jilin Uni…Phase 2

Levofolinic Acid + 5-FU continuous infusion + irinotecan HCl liposome ± cetuximab/bevacizumab (Levofolinic Acid + 5-FU continuous infusion + irinotecan HCl liposome ± cetuximab/bevacizumab)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleM.D. Anderson Cancer CenterPhase 2

Low Dose Bevacizumab (Low Dose Bevacizumab)

Brain Cancer; Glioblastoma · Brain Cancer

#BrainCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleNorton HealthcarePhase 2

Low-dose Intra-arterial Bevacizumab (Low-dose Intra-arterial Bevacizumab)

Radiation Necrosis · Radiation Necrosis

#RadiationNecrosis#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Bevacizumab Biosimilar Drug (MB02, MB02 (Bevacizumab Biosimilar Drug))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase3#항체#면역항체+2
효능 ORR 40.3%임상시험 1상태 ACTIVE

7 / 12 페이지

← 이전다음 →